Genocea Biosciences Inc. (NASDAQ:GNCA) shares were down 2.9% during trading on Thursday . The company traded as low as $5.24 and last traded at $5.29, with a volume of 141,066 shares trading hands. The stock had previously closed at $5.45.

A number of research analysts have recently commented on GNCA shares. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Tuesday, July 5th. FBR & Co reaffirmed a “buy” rating on shares of Genocea Biosciences in a research report on Monday, August 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Genocea Biosciences presently has a consensus rating of “Buy” and a consensus price target of $17.95.

The firm’s market cap is $148.19 million. The firm has a 50-day moving average price of $4.44 and a 200 day moving average price of $4.38.

Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.05. Equities research analysts predict that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.